KR20250020409A - 척수소뇌성 운동실조증을 치료하는 방법 - Google Patents

척수소뇌성 운동실조증을 치료하는 방법 Download PDF

Info

Publication number
KR20250020409A
KR20250020409A KR1020247038718A KR20247038718A KR20250020409A KR 20250020409 A KR20250020409 A KR 20250020409A KR 1020247038718 A KR1020247038718 A KR 1020247038718A KR 20247038718 A KR20247038718 A KR 20247038718A KR 20250020409 A KR20250020409 A KR 20250020409A
Authority
KR
South Korea
Prior art keywords
dosage form
patient
weeks
hydrochloride monohydrate
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247038718A
Other languages
English (en)
Korean (ko)
Inventor
블라디미르 코릭
멜리사 베이너
이르판 쿠레시
길버트 리탈리엔
Original Assignee
바이오하벤 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오하벤 테라퓨틱스 리미티드 filed Critical 바이오하벤 테라퓨틱스 리미티드
Publication of KR20250020409A publication Critical patent/KR20250020409A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247038718A 2022-05-23 2023-05-23 척수소뇌성 운동실조증을 치료하는 방법 Pending KR20250020409A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263344917P 2022-05-23 2022-05-23
US63/344,917 2022-05-23
PCT/US2023/067326 WO2023230451A2 (en) 2022-05-23 2023-05-23 Methods of treating spinocerebellar ataxias

Publications (1)

Publication Number Publication Date
KR20250020409A true KR20250020409A (ko) 2025-02-11

Family

ID=88920175

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247038718A Pending KR20250020409A (ko) 2022-05-23 2023-05-23 척수소뇌성 운동실조증을 치료하는 방법

Country Status (6)

Country Link
US (1) US20260124183A1 (cg-RX-API-DMAC7.html)
EP (1) EP4529485A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025517509A (cg-RX-API-DMAC7.html)
KR (1) KR20250020409A (cg-RX-API-DMAC7.html)
CN (1) CN120018855A (cg-RX-API-DMAC7.html)
WO (1) WO2023230451A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP2400349A1 (hu) * 2024-07-05 2026-01-28 Egis Gyógyszergyár Zrt. Troriluzole-hidroklorid-sók
WO2026062600A1 (en) * 2024-09-22 2026-03-26 Biohaven Therapeutics Ltd. Troriluzole for use in treating spinocerebellar ataxias

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018154462A2 (en) * 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
PT3706739T (pt) * 2017-11-12 2024-12-04 Biohaven Therapeutics Ltd Utilização de profármacos de riluzol para tratar ataxias
US20210308111A1 (en) * 2018-07-27 2021-10-07 With Great Power, Llc Clinical Methods And Pharmaceutical Compositions Employing AMPA Receptor Antagonists To Treat Glioblastoma And Other Cancers
US20230067811A1 (en) * 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease

Also Published As

Publication number Publication date
EP4529485A2 (en) 2025-04-02
WO2023230451A3 (en) 2024-01-04
JP2025517509A (ja) 2025-06-05
WO2023230451A2 (en) 2023-11-30
EP4529485A4 (en) 2026-05-20
CN120018855A (zh) 2025-05-16
US20260124183A1 (en) 2026-05-07

Similar Documents

Publication Publication Date Title
US12102618B2 (en) Use of riluzole prodrugs to treat ataxias
US10285981B2 (en) Compositions and methods for treating amyotrophic lateral sclerosis in responders
TW201034665A (en) Compositions and methods for using aminopyridines
US20260124183A1 (en) Methods of treating spinocerebellar ataxias
WO2014134569A1 (en) Compositions and methods for treating amyotrophic lateral sclerosis in responders
KR20120050512A (ko) 탈수초를 갖는 환자에서 4-아미노피리딘을 사용한 지속적 치료
WO2026011229A1 (en) Novel therapy
CN110831590A (zh) 含有培马贝特的医药
CA2753754C (en) Methods for treating schizophrenia
US20250375459A1 (en) Methods for ameliorating cognitive impairment using bile acid derivatives
US20250275953A1 (en) Vodobatinib for reducing progression of parkinson's disease
EA049071B1 (ru) Применение пролекарств рилузола для лечения атаксии
HK40033906B (en) Use of riluzole prodrugs to treat ataxias
HK40033906A (en) Use of riluzole prodrugs to treat ataxias
HK40037184A (en) Use of riluzole prodrugs to treat ataxias
HK1160586A (en) Durable treatment with 4-aminopyridine in patients with demyelination
EP2961404A1 (en) Compositions and methods for treating amyotrophic lateral sclerosis in responders

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000